BQ 788

an endothelin (B) receptor antagonist

Also Known As:

BQ-788; BQ788; N-2,6-dimethylpiperidinocarbonyl-gamma-MeLeu-Trp(COOMe)-Nle-ONa; N-cis-2,6-dimethylpiperidinocarbonyl-gamma-methylleucyl-tryptophyl(COOMe)-norleucine; sodium 2-((2-(((2,6-dimethyl-1-piperidinyl)carbonyl)amino)-4,4-dimethylpentanoyl)(1-(methoxycarbonyl)-D-tryptophyl)amino)hexanoate

Networked: 132 relevant articles (5 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Michinaga, Shotaro: 5 articles (01/2020 - 01/2014)
2.	Rae, Giles Alexander: 5 articles (01/2019 - 06/2006)
3.	Koyama, Yutaka: 4 articles (01/2020 - 01/2014)
4.	Chichorro, Juliana Geremias: 4 articles (01/2019 - 07/2006)
5.	Gulati, Anil: 4 articles (05/2014 - 01/2003)
6.	Webb, D J: 4 articles (09/2006 - 07/2000)
7.	Zampronio, Aleksander Roberto: 3 articles (02/2021 - 07/2006)
8.	Khodorova, Alla: 3 articles (07/2009 - 06/2006)
9.	D'Orléans-Juste, Pedro: 3 articles (05/2009 - 01/2006)
10.	Rae, Giles A: 3 articles (05/2009 - 01/2006)

Related Diseases

1.	Hypoxia (Hypoxemia) 01/01/2018 - "Furthermore, this rescue under extreme hypoxia can also be achieved using EDNRB-specific pharmacological agents, e.g., BQ-788. " 12/01/2002 - "The ET-RB antagonist BQ-788 increased in hypoxia-associated apoptosis of breast tumor cells in vitro. " 05/01/2012 - "BQ610 (but not BQ788) improved lung function, without altering alveolar development or increased TGF-β signaling in hypoxia-exposed animals. " 10/01/2021 - "ETBR antagonist BQ788 inhibited hypoxia-increased expressions of Nox1/4, superoxide anion production, and proliferation of cells. " 10/15/2012 - "Hypoxia, as well as ET-1, induced an increase in VEGF-A/-C and -D expression that was reduced in the presence of a selective ET(B)R antagonist, BQ788, and enhanced when ET-1 was administered under hypoxic conditions. "
2.	Pancreatitis 08/28/2012 - "In a second study, groups of animals with DBTC-induced pancreatitis were treated with endothelin (ET) receptor antagonists [ET-A (BQ123) and ET-B BQ788)]. " 08/28/2012 - "Treatments with the ET-A (BQ123) and ET-B (BQ-788) antagonists revealed significant protection against inflammatory pain related mechanical and thermal hypersensitivity behaviors in animals with pancreatitis (P < 0.05). "
3.	Insulin Resistance 06/01/2008 - "Preincubation with 1 micromol/L BQ-123 or BQ-788 for ETA- and ETB-receptor blockade, respectively, resulted in improved insulin sensitivity. " 03/01/2007 - "Seven patients (aged 58 +/- 2 years) with insulin resistance and coronary artery disease completed three hyperinsulinemic-euglycemic clamp protocols: a control clamp (saline infusion), during ET(A) receptor blockade (BQ123), and during combined ET(A) (BQ123) and ET(B) receptor blockade (BQ788). " 03/01/2006 - "A 60 minute intraarterial infusion of the ET(A) receptor antagonist BQ123 (10 nmol/min) combined with the ET(B) receptor antagonist BQ788 (5 nmol/min) evoked a significant increase in acetylcholine-mediated EDV (P < 0.01) in individuals with insulin resistance. "
4.	Cognitive Dysfunction 08/20/2015 - "BQ788 treatment completely blocked IRL-1620-induced improvement in cognitive impairment. " 05/01/2014 - "BQ788 treatment completely blocked IRL-1620 induced reduction in oxidative stress and cognitive impairment. "
5.	Pain (Aches) 08/28/2012 - "Treatments with the ET-A (BQ123) and ET-B (BQ-788) antagonists revealed significant protection against inflammatory pain related mechanical and thermal hypersensitivity behaviors in animals with pancreatitis (P < 0.05). " 01/01/2017 - "Intraplantar treatment with 30 nmol of clazosentan or BQ-788 reduced mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours, such as paw flinching (42% and 42%) and paw licking (38% and 62%), respectively. "

Related Drugs and Biologics

1.	cyclo(Trp-Asp-Pro-Val-Leu)
2.	BQ 610
3.	U 0126 (UO 126)
4.	Endothelins (Endothelin)
5.	PD 145065
6.	A 192621
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8.	Messenger RNA (mRNA)
9.	Gliotoxin
10.	Bosentan (Tracleer)

Related Therapies and Procedures

1.	Heart Transplantation (Grafting, Heart)
2.	Intravenous Administration
3.	Warm Ischemia
4.	Injections
5.	Vascular Access Devices (Arterial Line)